Health Affairs, 26, no. 2 (2007): 450-457 doi: 10.1377/hlthaff.26.2.450 © 2007 by Project HOPE	New Online   May/June Issue: Health Reform Revisited   Reform and '08 Election   Promoting off-label drug use information

This Article Figures Only Full Text (HTML) Reprint (PDF) Supplemental Exhibits Submit a response to this article View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scheffler, R. M. Articles by Levine, P. Search for Related Content PubMed Articles by Scheffler, R. M. Articles by Levine, P. Related Collections Business Of Health Consumer Issues International Issues Maternal And Child Health Mental Health/Substance Abuse Pharmaceuticals Health Spending

Health Tracking

TRENDS

The Global Market For ADHD Medications

Little is known about the global use and cost of medications for attention deficit hyperactivity disorder (ADHD). Global use of ADHD medications rose threefold from 1993 through 2003, whereas global spending (U.S. $2.4 billion in 2003) rose ninefold, adjusting for inflation. Per capita gross domestic product (GDP) robustly predicted use across countries, but the United States, Canada, and Australia showed significantly higher-than-predicted use. Use and spending grew in both developed and developing countries, but spending growth was concentrated in developed countries, which adopted more costly, long-acting formulations. Promoting optimal prescription and monitoring should be a priority.

                      What's this?

eLetters: